ELDN Eledon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ELDN

Price (delayed)

$2.41

Market cap

$59.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.64

Enterprise value

$55.57M

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring ...

Highlights
Eledon Pharmaceuticals's EPS has surged by 73% YoY and by 71% QoQ
The net income has soared by 55% from the previous quarter and by 54% YoY
The quick ratio has surged by 51% year-on-year but it has declined by 36% since the previous quarter
The company's equity fell by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://eledon.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ELDN
Market
Shares outstanding
24.81M
Market cap
$59.8M
Enterprise value
$55.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.7
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$40.33M
EBITDA
-$39.95M
Free cash flow
-$39.53M
Per share
EPS
-$1.64
Free cash flow per share
-$1.61
Book value per share
$3.45
Revenue per share
$0
TBVPS
$3.62
Balance sheet
Total assets
$89.07M
Total liabilities
$5.65M
Debt
$383,000
Equity
$83.42M
Working capital
$52.23M
Liquidity
Debt to equity
0
Current ratio
14.41
Quick ratio
13.12
Net debt/EBITDA
0.11
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-43.1%
Return on equity
-46.2%
Return on invested capital
-61.2%
Return on capital employed
-47.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELDN stock price

How has the Eledon Pharmaceuticals stock price performed over time
Intraday
4.78%
1 week
16.99%
1 month
42.6%
1 year
1.69%
YTD
33.89%
QTD
16.99%

Financial performance

How have Eledon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$43M
Net income
-$40.33M
Gross margin
N/A
Net margin
N/A
The net income has soared by 55% from the previous quarter and by 54% YoY
The operating income has surged by 53% since the previous quarter and by 51% year-on-year

Growth

What is Eledon Pharmaceuticals's growth rate over time

Valuation

What is Eledon Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.7
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eledon Pharmaceuticals's EPS has surged by 73% YoY and by 71% QoQ
The stock's price to book (P/B) is 75% more than its last 4 quarters average of 0.4 and 40% more than its 5-year quarterly average of 0.5
The company's equity fell by 9% QoQ

Efficiency

How efficient is Eledon Pharmaceuticals business performance
The return on invested capital has surged by 78% year-on-year and by 63% since the previous quarter
Eledon Pharmaceuticals's return on equity has surged by 55% QoQ and by 30% YoY
ELDN's return on assets has surged by 54% since the previous quarter and by 32% year-on-year

Dividends

What is ELDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELDN.

Financial health

How did Eledon Pharmaceuticals financials performed over time
The current ratio has soared by 57% year-on-year but it has declined by 34% since the previous quarter
The quick ratio has surged by 51% year-on-year but it has declined by 36% since the previous quarter
The debt is 100% smaller than the equity
The company's debt to equity has shrunk by 100% QoQ and by 100% YoY
The debt has declined by 49% year-on-year and by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.